Testicular Cancer Treatment and Outcomes Have Improved, Study Finds

A new study reveals that the prognosis of testicular cancer has notably improved. The findings were published in the Journal of Clinical Oncology.

While the classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has provided major advancements in the management of germ-cell tumors, the classifications rely on data from only 660 patients with testicular cancer treated between 1975 and 1990. Therefore, the investigators re-evaluated this classification in a database from a large international consortium of patients.

In this new study, researchers collated data on 2,451 men with metastatic seminoma who treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013. Clinical trial and registry data were included. The primary endpoints were defined as progression-free survival (PFS) and overall survival (OS), which were calculated from day 1 of treatment.


Compared with the initial IGCCCG classification, the researchers showed that in the modern series, 5-year PFS improved from 82% to 89% (95% CI, 87-90) while the 5-year OS increased from 86% to 95% (95% CI, 94-96) in good prognosis, and from 67% to 79% (95% CI, 70-85) and 72% to 88% (95% CI, 80-93) in intermediate prognosis patients. The next step, according to the investigators, will be to incorporate the findings  into treatment guidelines and reduce the burden of cancer therapy.